Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 27, 2013

View Archived Issues

Scientists at Tangrun Pharmaceuticals synthesize new HCV protease inhibitors

Takara Bio files gene therapy IND with Korean agency

EMA recommends approval of Sanofi Pasteur pediatric vaccine

Ignyta enters collaboration with Leiden University Medical Center

Nanologica to develop nanotechnology drugs with Russian biotech company

Antisense Pharma revises development strategy for anticancer candidate

CBK-201352 shows potent trypanotoxic activity in vitro and in vivo

Arrhythmogenic right ventricular dysplasia model established in vitro

Merck KGaA patents new LPA2 receptor antagonists

Novel agents for tuberculosis and cancer disclosed by CSIR

Researchers at the University of California synthesize novel GABA(A) receptor modulators

Japanese group discloses new ERRalpha inverse agonists

Novel first-in-class therapies hold promise in phase I for acute allergic reactions

Royalty Pharma proposes to acquire Elan

Mitsubishi Tanabe Pharma seeks additional indication for Tenelia in Japan

Shionogi applies for approval of Predonine in Japan

Isis Pharmaceuticals begins phase II study of ISIS-CRPRx in atrial fibrillation

Psyadon enrolls first patients in phase III study of ecopipam in Lesch-Nyhan disease

Inviragen develops dual-purpose recombinant MVA biodefense vaccine

Lytix Biopharma begins new phase II trial of LTX-109 for impetigo

Amarin files sNDA for Vascepa

United Therapeutics plans first clinical study of Pluristem's PLX-PAD cells in PAH

FDA approves Osphena for the treatment of dyspareunia

Arbovax creates tetravalent dengue virus vaccine

Likely delay to FDA review of Zohydro ER

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...